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https://doi.org/10.1016/j.stemcr.2018.11.002SUMMARYPredicting developmental potency and risk of posttransplantation tumor formation by human pluripotent stem cells (hPSCs) and their
derivatives largely rely on classical histological analysis of teratomas. Here, we investigated whether an assay based on microRNAs
(miRNA) in blood plasma is able to detect potentially malignant elements. Several hPSCs and human malignant germ cell tumor
(hGCT) lines were investigated in vitro and in vivo after mouse xenografting. The multiple conventional hPSC lines generated mature
teratomas, while xenografts from induced hPSCs (hiPSCs) with reactivated reprogramming transgenes and hGCT lines contained
undifferentiated and potentially malignant components. The presence of these elements was reflected in the mRNA andmiRNA profiles
of the xenografts withOCT3/4mRNA and themiR-371 andmiR-302 families readily detectable.miR-371 familymembers were also iden-
tified in mouse plasma faithfully reporting undifferentiated elements in the xenografts. This study demonstrated that undifferentiated
and potentially malignant cells could be detected in vivo.INTRODUCTION
The teratoma assay is still the most widely accepted
method for defining pluripotency of human stem cell lines.
Putative human pluripotent stem cells (hPSCs) are injected
into extra-uterine sites of immune-deficient mice where
they form xenografts. These tumors are often highly het-
erogeneous, composed of derivatives of all three embryonic
germ layers, ectoderm, endoderm, andmesoderm. They are
then referred to as teratomas, while teratocarcinomas
contain also malignant embryonal carcinoma (EC) cells
(Buta et al., 2013; Damjanov and Andrews, 2016). Yolk
sac (YS), an extraembryonic endodermal tissue, has also
been described in teratomas and teratocarcinomas. The
teratoma assay is laborious, animal-based, essentially qual-
itative, and rarely standardized, with inconsistencies re-
ported in methodology and histopathological evaluation
(Muller et al., 2010). To determine the clinical safety of
hPSC-based therapies, the ability to detect undifferentiated
PSCs and potentially malignant cells is extremely impor-
tant (Allison et al., 2018; Damjanov and Andrews, 2016).
In vitro tests such as PluriTest or ScoreCard, that describe
the expression of pluripotency or lineage markers have
been proposed as alternatives to the teratoma assay, but
these in vitro assays may miss detecting the malignantStem Cell Reports
This is an open access article under the Cpotential hPSCs (Allison et al., 2018; Bouma et al., 2017;
Muller et al., 2011; Tsankov et al., 2015). Another test,
called TeratoScore, based on quantifying gene expression
in xenografts, has shown good agreement with the tera-
toma assay with respect to identification of tissues derived
from the three germ layers, but ultimately only the tera-
toma assay has been shown to detect both pluripotency
and malignancy (Allison et al., 2018; Avior et al., 2015).
In human pathology, teratomas belong to a class of com-
plex neoplasms called germ cell tumors (human germ cell
tumor [hGCT]). During histopathological evaluation of
hGCTs, the presence of undifferentiated cells and YS ele-
ments are a clear indication of malignancy. The biological
significance of these elements is still debated in the context
of mouse xenografts derived from injection of hPSCs.
In the WHO pathology classification of tumors, various
hGCT types are distinguished, of which postpubertal
(type II) malignant hGCTs are of particular interest. Histo-
logically, these are referred to as either seminoma (SE) or
non-seminoma (NS). NS can represent all cell lineages
present during early embryogenesis, including somatic as
well as extra-somatic tissues such as YS tumor and chorio-
carcinoma. They all originate from EC cells, the malignant
counterpart of embryonic stem cells (ESCs) (Andrews et al.,
1980, 1984; Pera et al., 1989). EC cells, such as ESCs, arej Vol. 11 j 1493–1505 j December 11, 2018 j ª 2018 The Authors. 1493
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Figure 1. Schematic Representation of theWork FlowPerformed
hPSC (iPSCs and hESCs) and hGCT cell lines were injected subcu-
taneously into immunodeficient mice (teratoma assay). Cell lines
were karyotyped before injection and collected for mRNA and
miRNA analysis. During the teratoma assay, blood samples for
plasma preparation were timely collected until the tumors reached
the maximum allowed size of 2 cm3 (endpoint). At the endpoint,
xenografts were collected for histological characterization, and for
mRNA and miRNA isolation, and blood samples for plasma isolation
(_C, cell lines; _T, xenografts; and p, plasma samples). The mRNA
expression profile of the xenograft derived from hPSC and hGCT
lines was compared with a set of hGCTs from patients (Table S2). A
list of all abbreviations used in the study is given in Table S1A.characterized by expression of OCT3/4 and SOX2 (de Jong
et al., 2008; Looijenga et al., 2003), two transcription
factors also used to generate induced pluripotent stem cells
(iPSCs) (Takahashi and Yamanaka, 2006). This demon-
strates the similarities between hGCTs and hiPSCs (Cun-
ningham et al., 2012). All malignant hGCTs, with the
exception of teratomas (TE), are characterized by high
expression of a defined set of miRNAs (Gillis et al., 2007;
Looijenga et al., 2007). These include miR-371a-3p, -372-
3p, -373-3p, and -367-3p, which are also highly expressed
in hESCs and hiPSCs (Barroso-del Jesus et al., 2009; Lip-
china et al., 2012; Parr et al., 2016; Zhang et al., 2013).
ThesemiRNAs have been shown to be specific and sensitive
(liquid) biomarkers formalignant hGCTs in serum, plasma,
as well as cerebrospinal fluid of patients (Belge et al., 2012;
Dieckmann et al., 2012; Gillis et al., 2013; Lea˜o et al., 2018;
Murray et al., 2011; Syring et al., 2015; van Agthoven et al.,
2017).
In this study, we investigated whether plasma miRNAs
could serve as facile biomarkers to detect undifferentiated
and potentially malignant cell types in xenografts and in
plasma samples derived from mice injected with hPSC1494 Stem Cell Reports j Vol. 11 j 1493–1505 j December 11, 2018lines and hGCT cell lines. A set of hPSC lines and
hGCT cell lines was investigated after in vitro culture
and in vivo after being xenografted into mice. Each cell
line and corresponding xenografts were examined for
mRNA and miRNA expression. Patient-derived hGCTs
were included for comparison. In addition, mouse
plasma miRNA profiles were monitored over time during
xenograft formation. The results demonstrated that the
histological detection of undifferentiated and malignant
components in the xenografts could be predicted with
high accuracy on the basis of plasma miR-371a-3p levels.
We hypothesize that this could be of value in detecting
later malignancy should it arise in patients who have
undergone transplantation of differentiated hPSCs as
therapy.RESULTS
Design of the Study
The study design is shown schematically in Figure 1. Mul-
tiple hESC and hiPSC lines and (malignant) hGCTcell lines
were investigated (Table S1B). Each was examined for
mRNA and miRNA expression after culture in vitro and
in vivo after xenografting to mice, to investigate the extent
of similarity. The xenografts were also examined (immuno)
histologically by experienced pathologists. Matched serial
plasma samples were profiled for miRNA expression during
xenograft development and at the endpoint of the experi-
ment when mice were euthanized. A list of all abbrevia-
tions used is given in Table S1A.Histological Characterization of the Xenografts
Xenografts were morphologically characterized in H&E-
stained sections and by immunohistochemical detection
of OCT3/4, NANOG, CD30, SOX2, SOX17, and GPC3:
OCT3/4 and NANOG (Figure 2) to detect undifferentiated
hPSCs and potentially malignant elements (Ulbright
et al., 2014). CD30 is a survival factor and marker of trans-
formed human EC cells (Herszfeld et al., 2006). SOX17 is
informative for SE cells, SOX2 for EC, both being co-ex-
pressed with OCT3/4 and NANOG (Cheng et al., 2007;
Eini et al., 2014; Hart et al., 2005; Looijenga, 2009; Looi-
jenga et al., 2003; Rijlaarsdam et al., 2011). Glypican-3
(GPC3) identifies YS elements, associated with loss of
SOX2 and gain of SOX17 (in the absence of OCT3/4 and
NANOG) (Looijenga, 2009; Looijenga et al., 2003; Ulbright
et al., 2014). Representative H&E-stained sections are
shown in Figure 2. Xenografts derived from H9 hESCs
and the H9Hyb hESC line consisted only of fully differen-
tiated teratomas, confirming the immunohistochemical
findings. The Lu07 hiPSC line also consisted predomi-
nantly of differentiated derivatives of the three germ layers
(legend on next page)
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Figure 3. Principal-Component Analysis of mRNA Expression of
hPSCs, hPSC-Derived Xenografts, hGCT-Derived Cell Lines and
Xenografts and Primary Testicular hGCTs
The top 1,924 differentiating mRNAs (SD > 0.75) were used for
principal-component analysis. The first three components (ex-
plaining 72.7% of the variance) were plotted. The color code for the
different models (and specific culture conditions) is shown on the
right. The sample type is indicated by a specific symbol (culture,
dot; xenograft as square; hGCT as triangle). See also Figure S1.but had some YS elements (see below). Xenografts of all of
these cell lines contained somatic tissue structures repre-
senting all three germ layers (neural rosettes and retinal
pigmented epithelium [ectoderm], intestinal epithelium
[endoderm], cartilage, bone, fat, and muscle [mesoderm])
and they were negative for the pluripotency markers
OCT3/4 and NANOG. This is in line with previous immu-
nofluorescent staining for bIII-tubulin(ectoderm), human
a-fetoprotein (AFP, endoderm) and human PECAM-1
(CD31, mesoderm) (Bouma et al., 2017). By contrast, the
2102Ep xenografts consisted of EC, i.e., they had not un-
dergone somatic differentiation, as expected from their
tumor origin. Xenografts from the Lu07 + Dox hiPSC
line, in which the reprogramming genes had been reacti-
vated by giving the mice doxycycline (Dox) in their drink-
ing water, were mostly composed of EC components
resembling the 2102EpL xenografts, corresponding with
their immunohistochemical profiles (positive for OCT3/4,Figure 2. Histopathological Characterization of Xenografts Derive
(A–G) Representative pictures of H&E and immunohistochemistry of x
Lu07, (E) Lu07 + Dox and hGCT-derived cell lines, (F) 2102EpL, and (G
areas representing derivatives of mesoderm (Meso), ectoderm (Ecto), a
immunohistochemistry for the pluripotency markers OCT4 and specific
were counterstained with hematoxylin only. Scale bars, 100 mm (for t
(H) Summary of presence of tissues derived from the three embryonic
sac (YS) elements, and seminoma (SE) components in the xenograft.
small groups of cells positive for GPC3 (i.e., YS differentiation).
1496 Stem Cell Reports j Vol. 11 j 1493–1505 j December 11, 2018SOX2, and CD30), with small scattered areas positive for
GPC3 (i.e., YS), as also found in the Lu07 hiPSC line
without Dox. The TCam-2-derived xenograft showed
mixed pattern of SE, EC, and YS elements, again corre-
sponding to the immunohistochemical profile showing
heterogeneous staining for OCT3/4/SOX2/CD30 (for EC),
GPC3 (for YS), and OCT3/4 and SOX17 (SE). In summary,
H9 and H9Hyb hESC lines gave rise to xenografts that
were composed entirely of differentiated derivatives of
the three germ layers; they were therefore classified as TE
(Figure 2). The Lu07 hiPSC xenografts were predominantly
composed of tissues derived from the three germ layers
representing TE, but they also showed small scattered
groups of GPC3-positive cells, i.e., YS differentiation. These
YS cells were also found in the Lu07 + Dox xenografts with
reactivated reprogramming factors, although these were
otherwise predominantly composed of undifferentiated
cells identified as EC cells.mRNA Profiling
Previously, we reported the mRNA profiles of xenografts
from the Lu07 + Dox hiPSC line with reactivated reprog-
ramming transgenes and 2102EpL which completely
lacked differentiated elements in histology (Bouma
et al., 2017). To extend these datasets and to highlight
the similarities between these and hGCTs, we included
an additional series of hGCT-derived cell lines and pri-
mary testicular hGCTs, representing the various histolog-
ical elements and types of hGCTs, i.e., EC, YS tumors and
SEs (Table S2). To capture the major similarities between
these 74 samples, principal-component analysis (PCA) of
the top differentiating genes (4% of total) was performed.
The 3D PCA plot clearly resolved the cell cultures, xeno-
grafts, and hGCT groups (Figure 3). The Lu07 + Dox hiPSC
xenografts were separated from the xenografts derived
from H9 and H9Hyb hESCs and Lu07 hiPSCs without
Dox. Clustering using the top 99 differential probes
confirmed the overall PCA patterns (Figure S1) and also
showed the extensive overlap in expression between
hGCTs and the Lu07 + Dox hiPSC xenografts. Multiple
genes associated with ‘‘stem cell properties’’ and ‘‘malig-
nancy’’ were expressed in the Lu07 + Dox hiPSC xeno-
grafts. These mRNA profiles indicated that the majorityd from Different hPSC and hGCT Cell Lines
enografts derived from hPSCs (A) H9, (B) H9 + Dox, (C) H9Hyb, (D)
) TCam-2. H&E-stained xenografts (A–D) show differentiated tissue
nd endoderm (Endo). Scale bars, 200 mm. Representative images of
markers for hGCTs SOX17, SOX2, CD30, and GPC3 are shown. Nuclei
he immunohistochemistry images) (see Table S3 for antibody list).
germ layers, undifferentiated embryonal carcinoma (EC) cells, yolk
Notice that Lu07, although negative for all other markers, showed
(legend on next page)
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of the stem cell markers were not present in xenografts in
which there was full differentiation into mature TE, while
they remained high in Lu07 + Dox hiPSC xenografts, re-
flecting retention of their undifferentiated histology. The
Lu07 + Dox hiPSC tumors therefore resembled hGCTs
and the 2102EpL xenografts which also continued to ex-
press many pluripotency markers. Constitutive expression
of pluripotency genes thus confers classic features of
hGCTs in these hiPSC lines.
miRNA Profiling
The miRNA expression profile of the xenografts was
determined using TaqMan low-density arrays (TLDA
cards A&B). In total, 768 individual miRNAs were as-
sayed in the xenografts and compared with the profiles
of a set of control mouse organs, human EC cell lines
(NCCIT, 2102Ep, NT2), the SE cell line TCam-2, as well
as the undifferentiated hPSCs (Lu07 + Dox, Lu07, H9,
H9+Dox, and H9Hyb) cultured in vitro. The resulting
heatmap (Figure 4) showed the relative levels of the
top differentiating miRNAs (n = 57) in these samples
and indicated higher levels of the different members of
the miR-371, miR-302, and miR-518 families in the un-
differentiated Lu07 hiPSCs, with or without Dox,
Lu07 + Dox_T-derived xenografts, and the NCCIT,
2102Ep, NT2, and TCam-2 cells and xenografts. Xeno-
grafts consisting only of mature TE completely lacked
expression of these miRNAs. Many of these miRNA fam-
ilies are located in the primate-specific chromosome 19
miRNA cluster (C19MC, Figure 4), which has been impli-
cated in ESC function and specifically associated with
malignant hGCTs (Barroso-del Jesus et al., 2009; Lip-
china et al., 2012; Parr et al., 2016; Zhang et al., 2013)
but not with TE (Flor et al., 2016; Gillis et al., 2007;
Looijenga et al., 2007; Shen et al., 2018). A number of
downregulated miRNAs was also identified, including
members of the miR-34 cluster.
In light of these patterns of miRNAs and their apparent
reflection of the histological constitution of cell lines
in vitro and in vivo, mouse plasma miRNA levels were
examined at the endpoint of the xenograft, using the
TLDA card assays, and compared with t = 0 (before injec-
tion) as control. The same miRNA families (miR-371,
miR-302, and miR-518) distinguished plasma samplesFigure 4. miRNA Expression Profile Comparison between hPSCs a
The miRNA expression of hPSC cell lines (Lu07 + Dox_C, Lu07_C, H9
2102Ep_C, NT2_C, and TCam-2_C) and xenografts derived from the
H9Hyb_T) and hGCT (2102EpL_T and TCam-2_T) cell lines was dete
included as internal control (MusOrg). The heatmap shows 57 of the
majority of the samples (average Cq < 36). The color key shows the rel
Model are indicated on the right. miRNAs located in the primate specifi
available in Table S4.
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trol), and H9Hyb cell lines from mice injected with the
(malignant) Lu07 + Dox, 2102EpL, and TCam-2 cell lines
(Figure 5), being significantly expressed in the latter
group. In light of the high levels of significance of these
distinguishing markers, we then examined plasma
samples collected during xenograft development to
determine when the onset of potential malignant growth
was detectable. For each mouse investigated, 40 Ct values
of miRNA levels in all plasma samples and the calculated
tumor volume (mm3) were evaluated (Figures 6 and S2).
In mice transplanted with Lu07 (ST70) or Lu07 + Dox
(ST72) cells, plasma levels of the control miRNA (miR-
20a and 30b, both cross-reactive with mouse miRNAs)
remained stable throughout the experiment, while the
miR-371/2/3 and -367 accumulated in the plasma during
time. In the case of Lu07 + Dox mice, the time of detec-
tion was earlier and the levels were much higher than for
the condition without Dox. In both cases, detection of
circulating miRNAs in plasma preceded the detection of
the actual tumor by physical palpation. Additional time
series using mice xenografted with Lu07 hiPSCs,
2102EpL, and TCam-2 cells, confirmed these findings
(Figure S2). In all cases, the selected target miRNAs
were detected before the tumor became physically man-
ifest and the levels compared with control plasma were
generally >10 Ct (i.e., over 1,000-fold difference). The
finding of late plasma accumulation of miR-371/2/3
and -367 in mice transplanted with Lu07 cells without
Dox in the drinking water could be associated with the
histological finding of a minor YS element in the corre-
sponding xenograft (Figure 2). To resolve this further,
all available additional endpoint plasma samples of
mice with xenografts of H9 and H9Hyb hESCs and
Lu07 hiPSCs were evaluated for miR-371/373 and the
control miR-20a and -30b (Figure 7). The results showed
that mice with Lu07 hiPSCs without the addition of Dox
have low plasma levels of miR-371 and -373, while addi-
tion of Dox strongly enhanced these levels only in the
Lu07-transplanted mice and not in any without the
Dox-inducible reprogramming element in the genome.
The H9 and H9hybrid hESC lines also showed very low
plasma levels of these miRNAs at the endpoint of the
xenograft.nd hGCT-Derived Cell Lines and Respective Xenografts
_C, H9 + Dox_C, and H9Hyb_C), hGCT-derived cell lines (NCCIT_C,
respective hPSC (Lu07 + Dox_T, Lu07_T, H9_T, H9 + Dox_T, and
rmined and compared. miRNA profiles of NSG mouse organs were
768 examined miRNAs of which the levels were detectable in the
ative levels of the miRNAs. Color codes for specific Sample Type and
c chromosome 19miRNA cluster (C19MC) are indicated. Raw data are
Figure 5. MicroRNA Expression Profile of
the Xenograft Endpoint Plasma
Plasma samples (p) of mice xenografted with
Lu07 + Dox, Lu07, H9, H9 + Dox, H9Hyb,
2102EpL, and TCam-2 cells were profiled for
miRNA levels. Plasma samples of strain-,
age-, and sex-matched control mice were
included (n = 3, pMus). The heatmap of
20 targets, with average Cq < 36 is shown.
The color key shows the relative levels of the
miRNAs. Color codes for specific Sample Type
and Cell lines are indicated on the right.
miRNAs located in the primate specific
chromosome 19 miRNA cluster (C19MC) are
indicated. Spike-in miRNA levels were stable
in all samples (not shown). Raw data are
available in Table S4.DISCUSSION
In this study we determined mRNA and miRNA profiles of
cell lines, xenografts, and circulating miRNAs in matched
plasma of mice injected with multiple hPSCs and hGCTs
with various histological composition, and related these
to the expected teratoma and teratocarcinoma characteris-
tics. We demonstrated that expression levels of the miR-
371, -302, and C19MC families revealed the presence of
undifferentiated and malignant features in the Lu07 +
Dox hiPSCs, 2102EpL and TCam-2, both in cell cultures
and derivative tumors. Histologically, 2102EpL and
Lu07 + Dox hiPSC tumors were similar to each other, being
mainly composed of EC-like cells expressing the pluripo-
tency markers OCT3/4 and SOX2. TCam-2 xenografts
were diagnosed as mixed tumors containing SE, EC, and
YS elements. The designation ‘‘mixed tumor’’ for the
TCam-2 xenografts is in line with previously published
data showing that subcutaneous TCam-2 xenotransplanta-
tion initiates reprogramming into an EC-like fate
(Nettersheim et al., 2016). The H9 and H9Hyb, hESCs,
and Lu07 hiPSCs, formed TE containing differentiated cells
of the three germ layers and consistently lacked undifferen-
tiated cells (shown by histology and confirmed by immu-
nohistochemistry by the absence of OCT3/4 and NANOGexpression); the Lu07 hiPSC line in the absence of Dox
somewhat unexpectedly showed YS areas positive for
GPC3. In this set of xenografts and terminal plasma sam-
ples, levels of the miR-371, -302, and C19MC families
were below detection. These findings overlapped with pre-
viously reported human clinical pathology in which miR-
371-3, -302, and C19MC family were found expressed in
all testicular hGCTs except TE (Flor et al., 2016; Gillis
et al., 2007; Looijenga et al., 2007; Shen et al., 2018). In
particular, the miR-371 family has already proven to be a
reliable serum biomarker for testicular hGCTs in patients
(Belge et al., 2012; Dieckmann et al., 2012; Gillis et al.,
2013; Lea˜o et al., 2018; Murray et al., 2011; Syring et al.,
2015; van Agthoven et al., 2017), and we showed here
that it can be used to monitor tumor development with
minimum invasiveness without the need to terminate
the experiment. hGCTs much like as those derived here
from the injection of hPSCs, can present highly heteroge-
neous histology. AlthoughTE are assumed to be non-malig-
nant, it is recognized that they may contain a variable
number of residual undifferentiated cells, creating risk of
malignancy (Damjanov and Andrews, 2016; Terenziani
et al., 2015). However, malignancy features are rarely
discussed when interpreting results from the teratoma
assay. Teratomas are widely described in the stem cell fieldStem Cell Reports j Vol. 11 j 1493–1505 j December 11, 2018 1499
Figure 6. Time Course of miR-371, -372, -373, and -367 Accumulation in the Mouse Plasma Samples of Two Representative Mice
Injected with Lu07 (Right Panel) and Lu07 + Dox Cells (Left Panel)
Relative levels (40 Ct) of circulating miR-371, -372, -373, and -367 in the plasma of mice xenografted with Lu07 and Lu07 + Dox cells.
Plasma samples (p) were periodically collected until the endpoint of the experiment (max day 80). Tumor size is depicted in volume
(100 3 levels = mm3). miR-20a and miR-30b were used as internal references.as benign tumors composed of mature somatic tissue in
contrast to teratocarcinomas, the malignant counterparts
that include EC (Damjanov and Andrews, 2007; Muller
et al., 2010). This terminology contrasts with that used by
clinical pathologists because the description and analysis
of the malignant component is too limited; indeed EC is
not the only possible malignant component of hPSC-
derived tumors (Oosterhuis and Looijenga, 2005) and this
should be taken into account in considering potential
safety issues with transplantation of hPSC derivatives in
regenerative medicine. The initiating hPSCs have the
intrinsic capacity to differentiate into all three germ layers
of the embryo proper, but also into extraembryonic ele-
ments such as YS. Presence of YS is mostly neglected during
analysis of teratomas. It is noteworthy that this extraem-
bryonic endodermal tissue is associated with malignant
progression in pediatric TE (Gonzalez-Crussi et al., 1978;
Heiftz, 1998; O’Connor and Norris, 1994), and it shows
similarities with the behavior of ESCs (Oosterhuis and
Looijenga, 2005), including expression of the miR-371
and -302 families (Murray et al., 2011).
Following cell transplantation, plasma samples collected
from mice injected with Lu07, Lu07 + Dox, 2102EpL,
and TCam-2, showed increasing levels of miR-371/2/3
and -367 targets with time. The observation that the levels
plateaued inmost xenografted mice prior to the maximum
measured tumor size, suggests that production of miRNAs
is balanced by clearing from the circulation as was also
observed in patients after surgical removal of clinically
manifest hGCTs (Dieckmann et al., 2017; van Agthoven
et al., 2017). However, an alternative explanation might1500 Stem Cell Reports j Vol. 11 j 1493–1505 j December 11, 2018be that larger tumors may be less effective in releasing
miRNAs in the circulation, possibly due to reduced growth
and/or viability. This is, however, unlikely based on the
correlation found between the miRNA levels and the over-
all tumor load (Dieckmann et al., 2012; van Agthoven and
Looijenga, 2017). Interestingly, production of these
miRNAs was, at the end of the experiment, detected in
mice transplanted with Lu07 hiPSCs without Dox.
Although this was initially unexpected based on the avail-
able results derived from tissue and plasma miRNA
profiling (Figures 4 and 5), it is likely explained by the
presence of a minor YS component in the corresponding
xenografts. We showed in earlier work that a fraction of
Lu07 and Lu07 +Dox hiPSCs contained an additional short
arm of chromosome 12 (in Figure S1) (Bouma et al., 2017).
The correlation between karyotypic abnormalities and
their influence to malignant potential is still under discus-
sion (Allison et al., 2018).
In the Lu07 + Dox, 2102EpL, and TCam-2 malignant
xenografts, downregulation of the miR-34 cluster was
identified (Figure 4). Members of miR-34 family have
been shown to be p53 induced, and they act as tumor sup-
pressors regulating key cancer pathways (Rokavec et al.,
2014). This observation is therefore in line with the initial
model in which the miR-371 family was found to be an
alternativemechanism for inactivation of the P53 pathway
in hGCTs (Voorhoeve et al., 2006).
In conclusion, this study demonstrated the similarities
between hESCs, hiPSCs, and (malignant) hGCTs regarding
their histological composition, mRNA, miRNA, and pro-
tein expression profiles. This combined approach resulted
Figure 7. Levels of miR-371 and miR-373 for Endpoint Plasma
Samples of Mice Injected with H9, H9Hyb, Lu07, and Lu07 + Dox
Cell Lines
Relative levels (40 Ct) of circulating miR-371 and miR-373 in the
plasma (p) of mice xenografted with H9 (+ Dox and – Dox), H9Hyb,
Lu07 (+ Dox and – Dox). miR-20a and miR-30b were used as internal
references. The 40-Ct values are shown on the y axis. Endpoint
plasma samples derived from Lu07 + Dox injected mice have 100- to
1,000-fold higher levels of miR-371 and -373 compared with the
other lines. Mann-Whitney U test, independent samples; ***p <
0.005. Number of samples is indicated for each group.in an informative pre-clinical model, allowing investiga-
tion of various aspects of pluripotency regulation and
tumor risk prediction. Hence, it shows that evaluation of
circulating miRNAs in the plasma represents a real-time
refinement of the histological analysis of the teratoma
assay detecting undifferentiated, and possibly malignant
elements. Specifically, the elevated levels in liquid biopsies
of a defined set of embryonic miR, being miR-371, -302,
and C19MC family members, is of ultimate interest
because of their link to the presence of undifferentiated
and potentially malignant cell populations. The patterns
found in the mouse xenograft model mimic those in
hGCT patients. This observation may be expected to have
clinical value in development of a minimally invasive
method for monitoring development of malignancy inthe context of hESC and hiPSC applications in regenerative
medicine.EXPERIMENTAL PROCEDURES
Cell Lines and Patient Samples
Cell lines used in this study are summarized in Table S1B. hPSC
lines: hESC lines H9 and H9Hyb (H9 clone Hybrid_6), and hiPSC
LUMC007iCTRL01 (Lu07) (Bouma et al., 2017) were kindly
supplied by C. Freund, LUMC. The hiPSC Lu07 was generated
from skin fibroblasts using a Dox-inducible lentivirus encoding
mouse cDNAs for OCT3/4, SOX2, KLF4, and MYC separated
by three different 2A peptides (TetO-FUW-OSKM) and a lenti-
virus carrying the tetracycline-controllable transactivator (FUW-
M2rtTA, plasmids from Addgene) as already reported (Bouma
et al., 2017). Lu07 was cultured in the absence (Lu07) or presence
(Lu07 + Dox) of 1 mg/mL Dox (Sigma). As a control, H9 cells
were also cultured in the absence (H9) or presence of Dox
(H9 + Dox).
Five aneuploid (malignant) hGCT cell lines were used: TCam-2
representing SE (Mizuno et al., 1993), and four cell lines represent-
ing EC (NT2 [NTera-2]; Andrews et al., 1984), NCCIT (Teshima
et al., 1988), and two batches of 2102Ep (Andrews et al., 1980;
Josephson et al., 2007; Wang et al., 1980) [kindly supplied by P.
Andrews, Sheffield, UK]). 2102Ep was maintained at the Erasmus
Medical Center and the 2102EpL cultured at the LUMC, and
used for the xenograft experiments.
Cell lineswere characterized for genomic constitution (karyotyp-
ing) as described previously (Bouma et al., 2017) or verified for
identity by STR genotyping against the DSMZ (https://www.
dsmz.de/) database (hGCT cell lines).
In addition, for the human patient samples, a total of 25 primary
testicular hGCTs were included in the study. This series included:
15 pure SE and 10 NS of which the histological composition
(EC, TE, YS tumor, or SE) is indicated in the sample name
(Table S2). Histological diagnosis was performed by expert pathol-
ogists. Use of patient tissue samples remaining after diagnosis was
approved for research by the Medical Ethical Committee of the
EMC (the Netherlands), permit no. 02.981. This included permis-
sion to use the secondary tissue without further consent. Samples
were used according to the ‘‘Code for Proper Secondary Use of
Human Tissue in The Netherlands’’ developed by the Dutch
Federation of Medical Scientific Societies (FMWV, version, 2002;
update 2011).Teratoma Assay
Cells (1 3 106) were injected subcutaneously in the flank region
of 8- to 10-week-old male NSG mice (NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ, Charles River). Tumor growth was monitored
weekly by palpation, and mice were euthanized when tumors
reached a volume of %2 cm3. Tumor size was measured using
a digital caliper. Tumor volume was calculated according
to the method reported before (Feldman et al., 2009). Animal
experiments were approved by the Dutch Central Commis-
sion for Animal experimentation (Centrale Commissie voor
Dierproeven).Stem Cell Reports j Vol. 11 j 1493–1505 j December 11, 2018 1501
When indicated, Dox (2 mg/mL, Sigma-Aldrich) was provided
in the drinking water of the mice together with sucrose
(10 mg/mL, Sigma-Aldrich) 1 week prior to injections and was
renewed every 2 days for the duration of the experiment. Drink-
ing water without Dox contained sucrose only. Blood samples
were obtained from the animals before injections and every
7–14 days via tail bleeding. In some instances due to animal wel-
fare considerations the bleeding interval was minimally 7 days
but did not go beyond 14 days; for each bleeding, the maximum
amount of blood did not exceed 7.5% of the circulating
blood volume. Blood was collected in a 1.5-mL Eppendorf
tube (containing 7.5 mL of heparin 1,000 m/mL), centrifuged at
14,000 rpm for 5 min at 4C after which plasma was stored
at 80C until analysis.
Morphological and Immunohistochemical
Examination of Xenografts
Macroscopically representative parts of the tumors were snap
frozen (liquid nitrogen) as well as fixed in formalin and embedded
in paraffin (FFPE). H&E and various immunohistochemical stain-
ings (antibodies specified in Table S3) were performed (frozen
and FFPE) for evaluation as described previously (Bouma et al.,
2017; van Casteren et al., 2009). Evaluation was performed
independently by an experienced human pathologist in hGCTs
(J.W.O.) and a scientist (L.H.J.L.), as well as one European
board-certified veterinary pathologist (D.C.F.S.). Histological
classificationwas based on themost recentWHOclassification (Ul-
bright et al., 2016).
mRNA and miRNA Analysis
RNA from xenografts (_T) was isolated, labeled, and hybridized
onto the Illumina Human HT-12 v4 array (Illumina, San Diego,
CA, USA) and processed as described previously (Bouma et al.,
2017). In addition, total mRNA from cell lines (_C), and the
hGCT was profiled using Illumina HumanHT-12 v4, as described
previously (Van Der Zwan et al., 2013). Sample description is
provided in Table S2. Array data are available from ArrayExpress
(accession E-MTAB-6312). For miRNA profiling, total RNA was
extracted from cells and xenografts using the TRIzol reagent (In-
vitrogen) and miRVana miRNA Isolation Kit (Thermo Fischer
Scientific), respectively. All reagents for miRNA isolation and
quantification were obtained from Thermo Fisher Scientific
(www.thermofisher.com/). Total RNA was also prepared from a
mix of organs (brain, heart, kidney, testis, lungs, striated muscles,
lymph nodes, small, and large intestine) of an age-, sex-, and
strain-matching mouse following the same procedure adopted
for the xenografts. Plasma (p) of xenografted or control mice
(10–50 mL) was processed using the TaqMan miRNA ABC purifica-
tion Bead Kit human panel A or B (PN: 4473087/4473088, each
capturing 384 miRNAs) using the supplied protocol (PN:
4473439) and as described previously for human serum (Gillis
et al., 2013). miRNAs were converted into cDNA using the spe-
cific megaplex primers (PN: 4399966/4399967) and the reverse
transcription kit (PN; 3466596), pre-amplified (plasma) and quan-
titated on TaqMan low-density arrays (two 384-well Microfluids
TLDA cards, PN: 4398965/4398966) on a TaqMan 7900 thermo-
cycler using the supplier protocols (PN: 4399721). TaqMan1502 Stem Cell Reports j Vol. 11 j 1493–1505 j December 11, 2018miRNA array output data (sds files) were uploaded in the
Thermo Fisher Cloud App (https://www.thermofisher.com/
mysso/loginDisplay) and analyzed using defined threshold set-
tings for each individual miRNA. Cq values were exported (Table
S4), and globally normalized using QbasePlus (Biogazelle, Zwij-
naarde, Belgium). Individual assays for specific miRNAs (hsa-
miR-371a-3p, hsa-miR-372-3p, hsa-miR-373-3p, hsa-miR-367-3p,
hsa-miR-20a-5p, and hsa-miR-30b-5p; Thermo Fisher Scientific)
were run on a TaqMan 7500 fast thermocycler as described previ-
ously (van Agthoven et al., 2017). A non-human miRNA spike-in
ath-miR-159a was added to the plasma samples for quality
control of miRNA isolation and calibration (van Agthoven and
Looijenga, 2017).
Analysis of mRNA and miRNA Data
Heatmaps ofmRNA andmiRNA data were generated in R using the
‘‘pheatmap’’ clustering software package using default settings. For
mRNA clustering, ‘‘correlation’’ was used as the distance measure
for columns. PCA was performed using prcomp from the R Stats
package.
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